According to new data, BMS-986165, an oral, selective tyrosine kinase 2 inhibitor, may be safe and effective for treating plaque psoriasis…
Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer and editor. She is also a pharmacist at New York Presbyterian Hospital–Lower Manhattan campus. She has been a past guest lecturer at Touro College of Pharmacy in New York City for the Medical Writing elective. Dr Kaufman is a member of the New York City Society of Health-Systems Pharmacy, the New York State Council of Health-System Pharmacists, the Academy of Managed Care Pharmacy (AMCP)—Northeast Region Affiliate Chapter, the American Society of Consultant Pharmacists and the Empire State-Metropolitan NY Chapter of the American Medical Writers Association. She received her BS in Pharmacy from the University of Rhode Island (URI) College of Pharmacy and her Doctor of Pharmacy degree from Massachusetts College of Pharmacy and Allied Health Sciences in Boston. She also completed a Drug Information Fellowship at the URI Drug Information Center/Roger Williams Medical Center in Providence, R.I. Dr Kaufman is a registered pharmacist and is a Board-Certified Geriatric Pharmacist.
Articles by Michele B. Kaufman, PharmD, BCGP
Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA
A recent study suggests Zilretta, an intra-articular injection for OA knee pain, may lower blood glucose levels in OA patients…
Revised Application Expected for IV Meloxicam; Plus EU Approves Tildrakizumab
After meeting with the FDA, the makers of intravenous meloxicam plan to resubmit the treatment’s new drug application…
FDA Expands Safety Measures for Immediate Release Opioids
The FDA has expanded the new Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) to include immediate release opioids. The program, which also includes extended release and long acting opioids, will provide education to prescribers and healthcare professionals…
FDA Issues Safety Warning
The FDA is warning that patients with type 2 diabetes taking SGLT2 inhibitors may be at risk of developing a rare, serious infection, Fournier’s gangrene…
Piclidenoson in Trials for Psoriasis & RA; Plus Duzallo Approved in Europe
New clinical trials are underway to determine the safety and efficacy of piclidenoson for patients with plaque psoriasis and rheumatoid arthritis…
The FDA Denies Approval for Remoxy Extended Release; Plus Knee OA Pain Treatment Moves into Phase 3 Trials
The FDA has not approved extended release Remoxy, a gel capsule formulation of oxycodone, concluding that its potential benefits do not outweigh its risks…
Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
New research shows tanezumab may be safe and effective for patients with osteoarthritis pain…
EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray
In late July, the European Commission granted marketing approval for Hyrimoz, which is biosimilar to adalimumab…
Long-Term Apremilast Promising for Psoriatic Arthritis
In a long-term study, apremilast was well tolerated by patients with psoriatic arthritis, who showed sustained improvements for up to five years…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 43
- Next Page »